Notícias

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Is IEX a good stock to buy? We came across a bullish thesis on IDEX Corporation on Valueinvestorsclub.com by angus309. In this article, we will summarize the bulls’ thesis on IEX. IDEX Corporation’s share was trading at $214.93 as of May 1st. IEX’s trailing and forward P/E were 31.79 and 26.04 respectively according to Yahoo Finance. IDEX […]

IDEX (IEX) has drawn investor attention after recent trading, with the stock last closing at US$214.93 and showing positive returns over the past month and past 3 months. That performance now sits alongside a value score of 1. See our latest analysis for IDEX. While the share price slipped 1.3% over the last session, the 7 day share price return of 5.0% and year to date share price return of 20.0% suggest momentum has been building alongside a 1 year total shareholder return of 20.3%. If...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

IEX beats Q1 estimates and raises outlook as strong Health & Science Technologies demand and record orders signal momentum into 2026.

IDEX (NYSE:IEX) reported first-quarter 2026 results that management said came in above expectations, supported by growth in its targeted “advantage markets” and continued application of the company’s 80/20 operating philosophy. Quarterly performance and orders President and CEO Eric Ashleman said I

Moby summary of IDEX Corporation's Q1 2026 earnings call

IDEX delivered a strong first quarter and continue to see our growth strategies gain traction as we expand and integrate capabilities in targeted advantaged markets powered by 8020. In the first quarter, IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, which reflects a margin expansion of 50 basis points year-over-year. Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets.

The headline numbers for Idex (IEX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idex (IEX) delivered earnings and revenue surprises of +12.68% and +6.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?